Renal cell carcinoma (RCC) is the most common type of kidney or renal cancer, according to the American Cancer Society, with around 80-90% of the cancer cases reported being diagnosed as renal cell carcinoma. Transitional cell carcinoma (TCC) is another type of kidney cancer present among a few individuals (5% – 10% of the kidney cancer patients in the U.S.). At times, surgical treatment alone is not sufficient for treating RCC; if a person has developed metastatic cancer, he/she could be recommended for additional treatment regimens. Targeted therapies or immunotherapies are the most commonly prescribed treatments for kidney cancer. Targeted therapies are known to act at the cellular level, hence their accuracy and effectiveness increases with reduced toxicity. Therefore, kidney cancer drugs are among the only life-prolonging treatment regimens available for patients with advanced stage metastatic tumor.
This 82 page report gives readers a comprehensive overview of the Kidney Cancer Drugs Market. Browse through 5 data tables and 31 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/kidney-cancer-drugs-market.html
According to the report, the global kidney cancer drugs market is currently driven by multiple factors. At the top of this list is the growing number of patients that are afflicted with kidney cancer. Citations made in the report include findings by the World Cancer Research Fund International, which stated that by 2012, there were over 338,000 new cases of kidney cancer registered. Also known as renal cell carcinoma, kidney cancer constitutes 85% of the kidney-related tumors.
The report also includes discussions on the introduction of novel molecules into mainstream medicine after their approval as a cancer treatment method and the impact it will have on the global kidney cancer drugs market in the near future.However, the global kidney cancer drugs market is continually hampered by high drug prices, especially in case of branded drugs. Consequently, most consumers are turning to generic kidney cancer drugs, which is restraining the market’s growth rate.
New manufacturing trends in the global kidney cancer drugs market reveal that top players are shifting focus towards the developing economies and their emerging markets. Companies hope the new markets will open up sales of their kidney cancer drugs owing to the high population density of countries such as China and India.Key players in the global kidney cancer drugs market are GlaxoSmithKline, Novartis AG, and Pfizer. The report notes that over 40% of the global kidney cancer drugs market in 2013 was held by Pfizer, due to patent monopoly in branded kidney cancer drugs.
The report explains the growth rate in the global kidney cancer drugs market, with key focus on various drugs in it, including Nexavar, Afinitor, Sutent, Torisel, Proleukin, Inlyta, Avastin, and Votrient. Of these, Sutent held over 30% of the global kidney cancer drugs market. Sutent is the marketed version of Sunitinib, Pfizer’s drug in the global kidney cancer drugs market. It is the most-preferred drug in the market for now. Sutent is expected to exhibit at a low CAGR of 2.1% from 2016 to 2020, owing to its high price. On the other hand, Votrient is expected to exhibit a fast growth rate. It has already recorded a CAGR of 41.7% between 2012 and 2016.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving Kidney Cancer Drugs Market by 2020: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=537
The report also provides details on the major pipeline drugs in the global kidney cancer drugs market, including Dovitinib and Opdivo.Geographically, the global kidney cancer drugs market is led by North America, which held 45% of the market in 2013. A 6.0% CAGR is attributed to Asia Pacific owing to increasing demand for kidney cancer drugs in the region’s rapidly developing economy and increase in focus by top players on the region.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453